IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
Descripción
In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.
2 meses por 1 €
Después 4,99 € / mes · Cancela cuando quieras
- Podcasts exclusivos
- 20 horas de audiolibros / mes
- Podcast gratuitos
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option!